Lancet Study News

Covaxin meets WHO criteria for Delta, shows Lancet study: Bharat Biotech

Covaxin meets WHO criteria for Delta, shows Lancet study: Bharat Biotech

New Delhi: Commenting on the study of the Lancet Infectious Diseases on the effectiveness of COVAXIN (BBV152) against symptomatic RT-PCR, the Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among

India’s Covaxin only 50% effective against symptomatic Covid cases: Lancet study

India’s Covaxin only 50% effective against symptomatic Covid cases: Lancet study

New Delhi: Two-dose of Covaxin, developed by Hyderabad-based Bharat Biotech, provided only 50 per cent protection against the Covid-19 infection during the second wave of the pandemic in India, according to the first real-world assessment published in The Lancet Infectious Diseases journal on Wednesday. The study assessed 2,714 hospital workers